Status:
COMPLETED
Benepali® PEN Patient Satisfaction Survey
Lead Sponsor:
Biogen
Conditions:
Rheumatoid Arthritis
Spondyloarthropathies
Eligibility:
All Genders
18+ years
Brief Summary
The main aim of this study is to ascertain general satisfaction among participants with rheumatic diseases with day-to-day use of the Benepali® prefilled pen by means of a standardised participant que...
Eligibility Criteria
Inclusion
- Key
- Diagnosis of moderate to severe active rheumatoid arthritis, severe active and progressive rheumatoid arthritis, active and progressive psoriatic arthritis, severe active ankylosing spondylitis, or severe non-radiographic axial spondyloarthritis
- Current treatment with the Benepali® pre-filled pen in accordance with prescribing information for at least 3 months beforehand
- The patient has signed a declaration of consent to take part in the study
- Key
Exclusion
- Patients who are receiving Benepali® for the treatment of moderate to severe plaque psoriasis
- Patients who exhibit contraindications in accordance with the prescribing information for Benepali® and therefore treatment with Benepali ® is not indicated
- NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
August 10 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 21 2018
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT03327454
Start Date
August 10 2017
End Date
June 21 2018
Last Update
October 23 2018
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Altenholz, Germany, 24161
2
Research Site
Bad Neuenahr-Ahrweiler, Germany, 53474
3
Research Site
Berlin, Germany, 10117
4
Research Site
Berlin, Germany, 10719